These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 21159242)
21. Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS. Torsetnes SB; Levernæs MS; Broughton MN; Paus E; Halvorsen TG; Reubsaet L Anal Chem; 2014 Jul; 86(14):6983-92. PubMed ID: 24945626 [TBL] [Abstract][Full Text] [Related]
22. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy. Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241 [TBL] [Abstract][Full Text] [Related]
23. Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer. Han K; Chen Y; Sun X; Wen L; Wu Y; Chen S; Wei L; Yu J; Zeng T; Jiang L; Tan L Clin Transl Oncol; 2024 Oct; ():. PubMed ID: 39397200 [TBL] [Abstract][Full Text] [Related]
24. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. Ono A; Naito T; Ito I; Watanabe R; Shukuya T; Kenmotsu H; Tsuya A; Nakamura Y; Murakami H; Kaira K; Takahashi T; Kameya T; Nakajima T; Endo M; Yamamoto N Lung Cancer; 2012 Jun; 76(3):439-44. PubMed ID: 22300752 [TBL] [Abstract][Full Text] [Related]
25. Elevated progastrin-releasing peptide(31-98) concentrations in pleural effusions due to small-cell lung carcinoma. Shijubo N; Hirasawa M; Sasaki H; Igarashi T; Fujita A; Kodama T; Yamaguchi K; Abe S Respiration; 1996; 63(2):106-10. PubMed ID: 8966363 [TBL] [Abstract][Full Text] [Related]
26. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer. Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229 [TBL] [Abstract][Full Text] [Related]
27. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations. Trulson I; Klawonn F; von Pawel J; Holdenrieder S Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317 [TBL] [Abstract][Full Text] [Related]
28. Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer. Gong Z; Lu R; Xie S; Jiang M; Liu K; Xiao R; Shen J; Wang Y; Guo L Biochem Biophys Res Commun; 2016 Oct; 479(2):312-318. PubMed ID: 27639644 [TBL] [Abstract][Full Text] [Related]
29. Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma. Li Q; Sang S Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180443 [TBL] [Abstract][Full Text] [Related]
30. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951 [TBL] [Abstract][Full Text] [Related]
31. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
32. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of ProGRP for small cell lung cancer in different stages. Dong A; Zhang J; Chen X; Ren X; Zhang X J Thorac Dis; 2019 Apr; 11(4):1182-1189. PubMed ID: 31179060 [TBL] [Abstract][Full Text] [Related]
34. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. Muley T; Herth FJ; Heussel CP; Kriegsmann M; Thomas M; Meister M; Schneider MA; Wehnl B; Mang A; Holdenrieder S Tumour Biol; 2024; 46(s1):S219-S232. PubMed ID: 37840518 [TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer. Petrović M; Bukumirić Z; Zdravković V; Mitrović S; Atkinson HD; Jurišić V Med Oncol; 2014 Feb; 31(2):823. PubMed ID: 24375395 [TBL] [Abstract][Full Text] [Related]
36. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109 [TBL] [Abstract][Full Text] [Related]
37. [Study on the value of tumor markers ProGRP, CYFRA21-1, NSE and CEA in the differential diagnosis of pleural effusion]. Liu Y; Yu L; Lin J Zhongguo Fei Ai Za Zhi; 2006 Jun; 9(3):273-6. PubMed ID: 21172161 [TBL] [Abstract][Full Text] [Related]
38. Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer. Lyubimova NV; Kuz'minov AE; Markovich AA; Lebedeva AV; Timofeev YS; Stilidi IS; Kushlinskii NE Bull Exp Biol Med; 2022 Jun; 173(2):257-260. PubMed ID: 35737164 [TBL] [Abstract][Full Text] [Related]
39. ProGRP: a new biomarker for small cell lung cancer. Molina R; Filella X; Augé JM Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231 [TBL] [Abstract][Full Text] [Related]
40. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer. Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]